R.PR
REGISTERED-PRINCIPAL REGISTER
04/28/2026
Back to search
Official data from USPTO
NEUROTECH PHARMACEUTICALS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
04/28/2026
Trademark type
Combined
Nice classes
5, 10
Filing date
03/14/2024
Registration date
04/28/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/28/2026
Last transaction
04/28/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
06/04/2025
First use in commerce
06/04/2025
Drawing code
3
Owner type
03
Owner location
Cumberland, RI, US
Examiner
SCHLEGELMILCH, JONATHON A
Law office
L80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the word NEUROTECH over the word PHARMACEUTICALS to the right of a stylized eye.
Holders and representatives
Holders
Neurotech Pharmaceuticals, Inc.
Representatives
Emilia F. Cannella Ropes & Gray LLP
Technical classification
Nice Classes
Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the prevention and treatment of ophthalmic diseases and disorders; intravitreal implantsimplantable drug delivery devices sold filled with a pharmaceutical for the treatment of eye and vision conditions
Class 10
Medical devices for the prevention and treatment of ophthalmic diseases and disorders; medical deviceintraocular implant
Publications
History of USPTO decisions and trademark events.
25 publications found
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/07/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/07/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/03/2026
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/03/2026
IUAF
USE AMENDMENT FILED
10/07/2025
EISU
TEAS STATEMENT OF USE RECEIVED
10/07/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
05/27/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/01/2025
PUBO
PUBLISHED FOR OPPOSITION
04/01/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/26/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/05/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
03/05/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/05/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
03/05/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/05/2025
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
12/12/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
12/12/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/26/2024
GNRT
NON-FINAL ACTION E-MAILED
09/26/2024
CNRT
NON-FINAL ACTION WRITTEN
09/26/2024
DOCK
ASSIGNED TO EXAMINER
09/24/2024
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
08/06/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/06/2024
NWAP
NEW APPLICATION ENTERED
03/14/2024
Continuous trademark protection
Get notified about every new filing that threatens NEUROTECH PHARMACEUTICALS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.